Mesangial proliferative glomerulonephritis Medical Services in China

Mesangial proliferative glomerulonephritis (MesPGN) is a primary glomerular disease characterized by diffuse or focal hypercellularity of the mesangial area—due to increased mesangial cell number and/or expanded mesangial matrix—without significant endocapillary proliferation, crescent formation, or basement membrane duplication. It is a histopathological diagnosis typically confirmed via renal biopsy and classified under the broader umbrella of IgA nephropathy (IgAN) when immunoglobulin A (IgA) deposits dominate, or as non-IgA MesPGN when other immune complexes (e.g., IgG or IgM) predominate. Pathogenesis involves dysregulated mucosal immunity, abnormal glycosylation of IgA1 leading to autoantibody formation, immune complex deposition in the mesangium, and subsequent activation of complement (particularly the lectin and alternative pathways), triggering local inflammation, mesangial cell activation, cytokine release (e.g., PDGF, TGF-β), and extracellular matrix expansion. This cascade results in progressive glomerular sclerosis and, in some cases, tubulointerstitial fibrosis. Epidemiologically, MesPGN accounts for approximately 10–25% of all native kidney biopsies in East Asia, with higher prevalence in China, Japan, and Korea—likely reflecting both genetic susceptibility (e.g., HLA-DQ/DR variants) and environmental triggers such as recurrent mucosal infections. Globally, it is less common in Caucasian populations (<5% of biopsies). Peak incidence occurs in adolescents and young adults (ages 15–35), with a slight male predominance. Key risk factors include upper respiratory or gastrointestinal infections preceding onset, family history of IgAN or chronic kidney disease, smoking, obesity, uncontrolled hypertension, and persistent microscopic hematuria or proteinuria (>0.5 g/day). While many patients remain stable for years, ~20–30% progress to chronic kidney disease (CKD) stage 3+ over 10–20 years; a subset develops end-stage kidney disease requiring dialysis or transplantation. Quality of life is significantly impacted—not only by physical symptoms (fatigue, edema, hypertension-related headaches, reduced exercise tolerance) but also by psychological burden: anxiety about disease progression, treatment adherence challenges (e.g., long-term corticosteroids or immunosuppressants), dietary restrictions (low-sodium, low-protein), financial strain from repeated monitoring and therapy, and occupational limitations due to fatigue or frequent clinic visits. Patients often report diminished social engagement, sleep disturbances, and reduced health-related quality of life scores on validated instruments (e.g., KDQOL-SF™), particularly in domains of physical functioning, emotional well-being, and symptom burden.

Mesangial proliferative glomerulonephritis (MesPGN) is a histopathological pattern of glomerular injury characterized by increased mesangial cellularity and matrix expansion, typically identified on light microscopy, often accompanied by immunoglobulin A (IgA) or IgM deposition on immunofluorescence and electron-dense mesangial deposits on electron microscopy. It is not a single disease entity but rather a morphologic response to diverse underlying etiologies, broadly categorized as primary (idiopathic) or secondary. The most common primary cause is IgA nephropathy (IgAN), accounting for over 70% of cases in adults and adolescents in endemic regions; it results from aberrant mucosal immune responses leading to galactose-deficient IgA1 production, autoantibody formation, and subsequent immune complex deposition in the mesangium. IgM nephropathy—less common and more frequently observed in children—is another primary cause, associated with mesangial IgM and C3 deposits, though its precise pathogenesis remains incompletely defined. Secondary MesPGN arises in association with systemic diseases: autoimmune conditions such as systemic lupus erythematosus (SLE), particularly in Class II lupus nephritis, where immune complex deposition triggers mesangial proliferation; chronic infections including hepatitis B and C, HIV, and post-streptococcal states; and monoclonal gammopathies, especially IgA multiple myeloma or Waldenström macroglobulinemia, wherein paraprotein-driven complement activation and direct mesangial toxicity contribute to injury. Rarely, drug-induced forms occur, notably with nonsteroidal anti-inflammatory drugs (NSAIDs), pamidronate, or interferon-alpha therapy, likely via hemodynamic stress, direct cytotoxicity, or immune modulation.

Triggers are often episodic and linked to mucosal challenges: upper respiratory or gastrointestinal infections frequently precede clinical exacerbations in IgAN, suggesting antigen-driven flares. Physical exertion, dehydration, and acute febrile illness may transiently increase intraglomerular pressure and proteinuria, unmasking subclinical disease. In SLE-associated MesPGN, UV light exposure, hormonal fluctuations (e.g., pregnancy, estrogen therapy), and viral reactivation (e.g., Epstein-Barr virus) can precipitate disease activity.

Established risk factors include male sex (male-to-female ratio ~2:1 in IgAN), age at onset (peak incidence in second to fourth decades), persistent microscopic hematuria or episodic macroscopic hematuria, hypertension, obesity (BMI ≥25 kg/m²), and elevated serum uric acid levels—all independently associated with faster progression to chronic kidney disease (CKD). Smoking accelerates renal functional decline and increases proteinuria severity. Socioeconomic determinants—including low health literacy, limited access to nephrology care, and delayed diagnosis—contribute significantly to adverse outcomes, particularly in underserved populations.

Genetic susceptibility plays a substantial role. Genome-wide association studies (GWAS) have identified multiple risk loci, most robustly within the HLA-DQB1/DRB1 region on chromosome 6p21, implicating antigen presentation dysregulation. Polymorphisms in genes involved in IgA glycosylation (e.g., C1GALT1, C1GALT1C1), complement regulation (CFH, CD46), and innate immunity (TNFSF13, DEFA) further modulate disease susceptibility and phenotype. Familial clustering occurs in up to 10% of IgAN cases, and first-degree relatives of affected individuals demonstrate higher prevalence of galactose-deficient IgA1 and subclinical hematuria. Notably, APOL1 high-risk genotypes (G1/G2) are associated with more aggressive MesPGN phenotypes in individuals of African ancestry, independent of SLE or HIV status.

Environmental exposures interact with genetic background to shape disease expression. Endemic geographic variation—higher incidence in East Asia, Southern Europe, and Australia—suggests environmental co-factors, potentially including dietary patterns (e.g., high sodium intake promoting intraglomerular hypertension), air pollution (PM2.5 linked to systemic inflammation and endothelial dysfunction), and endemic pathogens (e.g., Helicobacter pylori, which may promote cross-reactive IgA responses). Occupational exposure to solvents or heavy metals has been anecdotally reported but lacks robust epidemiologic validation. Importantly, gut microbiota composition influences mucosal immunity and IgA production; dysbiosis—induced by antibiotics, Western diet, or chronic constipation—may promote aberrant IgA1 glycosylation and mesangial deposition. Collectively, MesPGN emerges from a complex interplay of inherited immune dysregulation, environmental antigenic challenges, and modifiable lifestyle and socioeconomic determinants—underscoring the need for integrated, personalized risk stratification and early intervention strategies in nephrology practice.

Mesangial proliferative glomerulonephritis (MesPGN) is a histopathologically defined primary glomerular disease characterized by diffuse or focal hypercellularity of the mesangial area due to increased mesangial cell number and/or expanded mesangial matrix, without significant endocapillary proliferation, crescent formation, or necrotizing lesions. It represents a heterogeneous clinicopathologic entity commonly associated with IgA nephropathy (IgAN), IgM nephropathy, or idiopathic forms, and less frequently with systemic diseases such as lupus nephritis (Class II) or post-infectious GN. Clinical presentation varies widely—from asymptomatic urinary abnormalities to overt nephritic or nephrotic syndrome—depending on the underlying etiology, degree of mesangial involvement, and rate of progression.

Early symptoms are often subtle and nonspecific. Many patients are identified incidentally during routine urinalysis or health screening. Microscopic hematuria—detected via dipstick or microscopic examination—is the most common initial finding, present in over 80% of cases, particularly in IgA-associated MesPGN. It may be persistent or episodic, sometimes triggered by mucosal infections (e.g., upper respiratory tract infections), a hallmark of synpharyngitic hematuria in IgAN. Mild proteinuria (<1 g/day) is also frequent early on; however, it is typically subnephrotic and may go unnoticed without quantitative assessment. Hypertension is uncommon at onset but may emerge subtly with declining renal function. Fatigue, mild edema (especially periorbital), or unexplained foamy urine may prompt evaluation but are rarely isolated early features. Importantly, serum creatinine remains normal in early stages, and estimated glomerular filtration rate (eGFR) is preserved, reflecting the relatively indolent nature of early disease.

Typical symptoms reflect more pronounced glomerular injury. Persistent or recurrent macroscopic hematuria—often self-limited but alarming—occurs in approximately 30–40% of patients, especially younger adults with IgAN. Nephrotic-range proteinuria (≥3.5 g/day) develops in 15–25% of cases, usually in those with extensive mesangial expansion or concomitant podocyte injury, leading to peripheral edema (ankle, sacral, or periorbital), hypoalbuminemia, hyperlipidemia, and increased risk of thromboembolism. Nephritic syndrome—characterized by hematuria, hypertension, oliguria, and mild-to-moderate proteinuria (<3.5 g/day)—may manifest acutely, particularly following infection or in rapidly progressive variants. Hypertension becomes more prevalent as renal vascular resistance increases and sodium retention ensues; it is present in ~20–35% at diagnosis and portends worse long-term outcomes. Some patients exhibit isolated asymptomatic proteinuria or isolated hematuria without systemic signs, underscoring the necessity for comprehensive urinalysis and renal function testing.

Accompanying symptoms are largely driven by comorbidities or secondary effects. Patients with IgA-dominant MesPGN may report recurrent pharyngitis, sinusitis, or gastrointestinal infections preceding hematuria flares. Arthralgia, low-grade fever, or mild abdominal discomfort occur occasionally but are not diagnostic. In secondary forms (e.g., lupus-associated), constitutional symptoms such as malar rash, photosensitivity, oral ulcers, or arthralgias may coexist. Chronic kidney disease–related symptoms—including nocturia, reduced exercise tolerance, and mild cognitive slowing—emerge only with progressive eGFR decline. Anemia (normocytic, normochromic) may develop insidiously due to reduced erythropoietin production. Hyperkalemia or metabolic acidosis are rare in early or moderate stages but signal advanced parenchymal loss.

Complications arise from persistent inflammation, progressive fibrosis, and functional impairment. The most consequential is chronic kidney disease (CKD), progressing to end-stage renal disease (ESRD) in 15–30% of high-risk patients over 10–20 years—particularly those with sustained proteinuria >1 g/day, hypertension, impaired baseline eGFR, or interstitial fibrosis/tubular atrophy on biopsy. Acute kidney injury (AKI) can occur secondary to severe crescentic transformation (rare in classic MesPGN but possible in overlapping phenotypes), volume depletion during macroscopic hematuria episodes, or drug-induced nephrotoxicity (e.g., NSAIDs). Nephrotic syndrome confers risks of spontaneous bacterial peritonitis, deep vein thrombosis, pulmonary embolism, and acute coronary syndromes due to hypercoagulability and dyslipidemia. Hypertensive emergencies and left ventricular hypertrophy may develop with longstanding uncontrolled blood pressure. Rarely, rapidly progressive glomerulonephritis (RPGN) evolves if cellular crescents appear, indicating aggressive immune-mediated injury beyond typical mesangial proliferation.

Diagnosis relies on integration of clinical, laboratory, and histopathologic data. Urinalysis reveals dysmorphic red blood cells and red blood cell casts (suggestive of glomerular origin); quantitative urine protein-to-creatinine ratio (UPCR) or 24-hour urine collection confirms proteinuria severity. Serum studies include creatinine, eGFR, albumin, complement levels (C3, C4—typically normal in idiopathic/IgA forms but low in lupus or post-infectious GN), ANA, anti-dsDNA, ANCA, hepatitis serologies, and serum IgA levels (elevated in ~50% of IgAN). Renal ultrasound shows normal or slightly reduced kidney size with preserved corticomedullary differentiation; echogenicity may increase with fibrosis. Definitive diagnosis requires percutaneous renal biopsy with light microscopy (showing mesangial hypercellularity ± matrix expansion), immunofluorescence (IgA-dominant deposits in IgAN; IgM in IgM nephropathy; IgG/C3 in lupus), and electron microscopy (mesangial electron-dense deposits). Biopsy is indicated in patients with persistent hematuria/proteinuria, declining eGFR, or atypical features.

Differential diagnosis includes other primary glomerulopathies: minimal change disease (absent hematuria, normal biopsy LM/IF, foot process effacement on EM), focal segmental glomerulosclerosis (FSGS) (segmental scarring, hyalinosis, variable hematuria), membranoproliferative GN (MPGN) (subendothelial deposits, 'tram-track' appearance, low C3), and thin basement membrane nephropathy (benign familial hematuria, normal proteinuria, no progression). Secondary causes must be excluded: lupus nephritis (Class II or III), Henoch-Schönlein purpura (identical renal histology to IgAN but with systemic vasculitis), post-streptococcal GN (low C3, elevated ASO titers, post-infectious timeline), and cryoglobulinemic GN (associated with hepatitis C, palpable purpura, arthralgias). Importantly, MesPGN must be distinguished from early diabetic nephropathy (which may show mesangial expansion but lacks true hypercellularity and occurs in context of diabetes duration, retinopathy, and absence of immune deposits). Accurate classification guides prognosis and therapy—e.g., tonsillectomy and corticosteroids in select IgAN, immunosuppression in lupus-related disease, or supportive care in idiopathic forms.

Mesangial proliferative glomerulonephritis (MesPGN) is a histopathologically heterogeneous primary glomerular disease characterized by diffuse or focal mesangial cell hyperplasia and increased mesangial matrix, typically identified on light microscopy. It encompasses a spectrum ranging from mild idiopathic forms to those associated with systemic diseases such as IgA nephropathy (the most common variant), lupus nephritis (Class II), or post-infectious glomerulonephritis. Clinical presentation varies widely—from asymptomatic microscopic hematuria and/or proteinuria to nephrotic-range proteinuria, hypertension, or impaired renal function. Accurate diagnosis requires renal biopsy with integrated evaluation of light microscopy, immunofluorescence, and electron microscopy to distinguish etiologies and guide prognosis and therapy.

Conservative management forms the cornerstone of early or low-risk MesPGN. This includes strict blood pressure control targeting <130/80 mmHg using renin-angiotensin-aldosterone system (RAAS) inhibitors—specifically angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs)—which reduce intraglomerular pressure, attenuate proteinuria, and slow progression of glomerulosclerosis. Dietary modifications are essential: sodium restriction (<2 g/day), moderate protein intake (0.8–1.0 g/kg/day in non-nephrotic patients; lower if GFR <60 mL/min/1.73m²), and avoidance of nephrotoxic agents (e.g., NSAIDs, contrast media). Smoking cessation, weight optimization, and regular monitoring of serum creatinine, estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR), and complement levels (C3, C4) are integral to longitudinal care. In IgA-dominant MesPGN, tonsillectomy may be considered in select endemic regions (e.g., Japan) with recurrent macroscopic hematuria and active mucosal inflammation, though evidence remains limited and controversial outside specific cohorts.

Pharmacologic intervention is stratified by histologic severity, clinical phenotype, and risk of progression. For patients with persistent proteinuria >1 g/day despite 3–6 months of optimized RAAS blockade—and particularly those with crescents, interstitial fibrosis, or declining eGFR—immunosuppression is indicated. First-line regimens include corticosteroids: oral prednisone (0.8–1.0 mg/kg/day for 1–2 months, followed by taper over 4–6 months) or pulse methylprednisolone (500–1000 mg IV × 3 days) in severe presentations. In high-risk IgA nephropathy–associated MesPGN, the combination of corticosteroids plus mycophenolate mofetil (MMF) (0.75–1.0 g twice daily) has demonstrated superior proteinuria reduction and eGFR preservation compared to steroids alone in randomized trials (e.g., TESTING trial, modified protocol). Calcineurin inhibitors (cyclosporine A or tacrolimus) may be used as steroid-sparing agents in refractory cases, though require careful therapeutic drug monitoring due to nephrotoxic potential. Emerging biologics—including targeted-release budesonide (Nefecon®), which delivers corticosteroid selectively to gut-associated lymphoid tissue to modulate aberrant IgA1 production—are now approved in several jurisdictions for primary IgA nephropathy and represent a paradigm shift toward pathophysiology-driven therapy. Rituximab is reserved for rare, autoantibody-mediated or relapsing forms unresponsive to conventional agents. Anticoagulation or antiplatelet therapy is not routinely recommended unless comorbid thrombotic microangiopathy or antiphospholipid syndrome is confirmed.

Surgical treatment plays no primary role in MesPGN. Nephrectomy is contraindicated except in extraordinary circumstances—such as life-threatening hemorrhage from massive cortical necrosis (extremely rare) or end-stage kidney disease (ESKD) requiring transplantation. Kidney transplantation is highly successful in MesPGN, with 5-year graft survival exceeding 90% in most series. However, recurrence rates vary by subtype: ~50% in IgA nephropathy–associated MesPGN (often subclinical), <10% in lupus-related MesPGN, and negligible in idiopathic forms. Pre-transplant evaluation must assess disease activity, cardiovascular risk, and infection screening (especially hepatitis B/C, TB, CMV). Living donor transplantation is preferred when feasible, given shorter wait times and superior outcomes.

China offers distinct advantages in MesPGN management, rooted in its large-scale clinical infrastructure, standardized biopsy protocols, and integration of traditional Chinese medicine (TCM) within evidence-based frameworks. Major academic centers (e.g., Peking University First Hospital, Shanghai Renji Hospital) perform over 10,000 native kidney biopsies annually, enabling rapid histopathologic classification and real-time multidisciplinary review. The Chinese Society of Nephrology’s clinical practice guidelines emphasize individualized immunosuppression based on risk stratification models incorporating Oxford MEST-C scores and genomic biomarkers. Moreover, China leads global research in TCM–allopathy synergy: rigorous RCTs support adjunctive use of Huangkui Capsule (extract of Abelmoschus manihot) and Tripterygium wilfordii polyglycoside (TWP) for reducing proteinuria and stabilizing eGFR, with favorable safety profiles when monitored for hepatotoxicity and gonadal suppression. National health insurance coverage for ACEIs/ARBs, MMF, and newer agents like Nefecon® (recently approved) enhances accessibility. Tele-nephrology platforms facilitate rural follow-up, while AI-assisted pathology tools improve diagnostic consistency across tiered hospitals.

Recovery and long-term prognosis depend critically on adherence and surveillance. Patients should undergo quarterly assessments of UACR, eGFR, and blood pressure; semiannual lipid panels and bone mineral density screening (if on prolonged steroids); and annual ophthalmologic exams. Vaccination against influenza, pneumococcus, and hepatitis B is strongly advised. Physical activity should be encouraged (≥150 min/week moderate aerobic exercise), but contact sports are discouraged during active hematuria or significant proteinuria. Psychosocial support—including counseling and peer networks—is vital, as chronic kidney disease correlates with elevated depression and anxiety prevalence. Pregnancy requires preconception counseling: conception is safe only with stable renal function (eGFR >70 mL/min/1.73m²), proteinuria <1 g/day, and BP <140/90 mmHg on pregnancy-compatible antihypertensives (e.g., labetalol, nifedipine). Finally, patients must understand that MesPGN is often indolent but unpredictable—early intervention, consistent monitoring, and shared decision-making significantly improve 10-year renal survival, with >85% of low-risk patients maintaining eGFR >60 mL/min/1.73m² at decade follow-up.